488例FIGO 2018 Ⅲc期子宫颈鳞癌患者的治疗及预后分析
回顾性分析浙江省肿瘤医院2013年5月至2015年5月收治的488例FIGO 2018 Ⅲc期子宫颈鳞癌患者,按治疗方式分为手术联合术后辅助放化疗组(324例)与根治性放疗±同步化疗组(164例)。Ⅲc1期手术组7年生存率83.6%高于放疗组52.9%(P<0.001);Ⅲc2期及髂总淋巴结转移患者两组生存率无显著差异。结论认为符合手术条件的Ⅲc1期患者两种方式均可接受,Ⅲc2期或髂总淋巴结转移者推荐根治性放疗±同步化疗。
要点
- Ⅲc1期手术组7年生存率83.6%高于放疗组52.9%(P<0.001)。
- Ⅲc2期手术组7年生存率48.0%与放疗组33.3%比较无显著差异(P=0.296)。
- 髂总淋巴结转移者手术组7年生存率73.8%与放疗组57.4%比较无显著差异(P=0.051)。
核心结论
- 对于符合手术条件的Ⅲc1期子宫颈鳞癌患者,即使肿瘤最大径≥4 cm,无论是否存在盆腔淋巴结转移(不包括髂总淋巴结转移),根治性手术联合术后辅助放化疗和根治性放疗±同步化疗均为可接受的治疗方式。
- 对于Ⅲc2期或髂总淋巴结有转移的子宫颈鳞癌患者,两种治疗方式患者的生存率无明显差异,基于治疗时长和经济学考虑,推荐患者选用根治性放疗±同步化疗方案。
研究设计与样本
- 回顾性分析2013年5月至2015年5月浙江省肿瘤医院收治的488例FIGO 2018 Ⅲc期子宫颈鳞癌患者,年龄(57.9±11.3)岁。
- 按治疗方式分为手术组(子宫颈癌根治性手术联合术后辅助放化疗,324例)和放疗组(子宫颈癌根治性放疗±同步化疗,164例)。
- 随访截至2022年5月,随访时间(96±12)个月(范围84~108个月)。
主要发现
- Ⅲc1期手术组7年生存率83.6%(250/299)高于放疗组52.9%(74/140),差异有统计学意义(P<0.001)。
- Ⅲc2期手术组7年生存率48.0%(12/25)与放疗组33.3%(8/24)比较,差异无统计学意义(P=0.296)。
- 肿瘤最大径≥4 cm的Ⅲc1期患者中,手术组7年生存率81.2%(112/138)高于放疗组51.9%(56/108),差异有统计学意义(P<0.001)。
- 放疗组中原FIGO 2009分期Ⅱb期且肿瘤最大径≥4 cm的46例患者7年生存率67.4%,与手术组81.2%比较差异无统计学意义(P=0.052)。
关键数值与推荐
- 手术组淋巴囊肿发生率30.2%(98/324)高于放疗组0(0/164),肠梗阻发生率7.7%(25/324)高于放疗组1.2%(2/164),差异均有统计学意义(P均<0.01)。
- 手术组输尿管梗阻发生率8.3%(27/324)低于放疗组36.0%(59/164),急性放射性肠炎发生率54.3%(176/324)低于放疗组73.2%(120/164),慢性放射性肠炎发生率7.4%(24/324)低于放疗组20.7%(34/164),差异均有统计学意义(P均<0.01)。
临床怎么用
- 作者认为,对符合手术条件的Ⅲc1期患者,即使肿瘤最大径≥4 cm,手术联合术后辅助放化疗与根治性放疗±同步化疗均为可接受的治疗方式。
- 作者推荐Ⅲc2期或髂总淋巴结有转移的患者选用根治性放疗±同步化疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the treatment and prognosis of patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stage Ⅲc cervical squamous cell carcinoma. Methods: A total of 488 patients at Zhejiang Cancer Hospital between May, 2013 to May, 2015 were enrolled. The clinical characteristics and prognosis were compared according to the treatment mode (surgery combined with postoperative chemoradiotherapy vs radical concurrent chemoradiotherapy). The median follow-up time was (96±12) months ( range time from 84 to 108 months). Results: (1) The data were divided into surgery combined with chemoradiotherapy group (surgery group) and concurrent chemoradiotherapy group (radiotherapy group), including 324 cases in the surgery group and 164 cases in the radiotherapy group. There were significant differences in Eastern Cooperation Oncology Group (ECOG) score, FIGO 2018 stage, large tumors (≥4 cm), total treatment time and total treatment cost between the two groups (all P<0.01). (2) Prognosis: ① for stage Ⅲc1 patients, there were 299 patients in the surgery group with 250 patients survived (83.6%). In the radiotherapy group, 74 patients survived (52.9%). The difference of survival rates between the two groups was statistically significant (P<0.001). For stage Ⅲc2 patients, there were 25 patients in surgery group with 12 patients survived (48.0%). In the radiotherapy group, there were 24 cases, 8 cases survived, the survival rate was 33.3%. There was no significant difference between the two groups (P=0.296). ② For patients with large tumors (≥4 cm) in the surgery group, there were 138 patients in the Ⅲc1 group with 112 patients survived (81.2%); in the radiotherapy group, there were 108 cases with 56 cases survived (51.9%). The difference between the two groups was statistically significant (P<0.001). Large tumors accounted for 46.2% (138/299) vs 77.1% (108/140) in the surgery group and radiotherapy group. The difference between the two groups was statistically significant (P<0.001). Further stratified analysis, a total of 46 patients with large tumors of FIGO 2009 stage Ⅱb in the radiotherapy group were extracted, and the survival rate was 67.4%, there was no significant difference compared with the surgery group (81.2%; P=0.052). ③ Of 126 patients with common iliac lymph node, 83 patients survived, with a survival rate of 65.9% (83/126). In the surgery group, 48 patients survived and 17 died, with a survival rate of 73.8%. In the radiotherapy group, 35 patients survived and 26 died, with a survival rate of 57.4%. There were no significant difference between the two groups (P=0.051). (3) Side effects: the incidence of lymphocysts and intestinal obstruction in the surgery group were higher than those in the radiotherapy group, and the incidence of ureteral obstruction and acute and chronic radiation enteritis were lower than those in the radiotherapy group, and there were statistically significant differences (all P<0.01). Conclusions: For stage Ⅲc1 patients who meet the conditions for surgery, surgery combined with postoperative adjuvant chemoradiotherapy and radical chemoradiotherapy are acceptable treatment methods regardless of pelvic lymph node metastasis (excluding common iliac lymph node metastasis), even if the maximum diameter of the tumor is ≥4 cm. For patients with common iliac lymph node metastasis and stage Ⅲc2, there is no significant difference in the survival rate between the two treatment methods. Based on the duration of treatment and economic considerations, concurrent chemoradiotherapy is recommended for the patients. 目的: 分析国际妇产科联盟2018年(FIGO 2018)分期Ⅲc期子宫颈鳞癌患者的治疗及预后。 方法: 收集2013年5月至2015年5月浙江省肿瘤医院收治的临床病理资料及随访资料完整的488例子宫颈鳞癌患者进行回顾性分析,患者年龄为(57.9±11.3)岁。根据治疗方式的不同分为手术组(子宫颈癌根治性手术联合术后辅助放化疗,324例)和放疗组(子宫颈癌根治性放疗±同步化疗,164例),比较两组患者的临床特点、预后及并发症发生率。随访截至2022年5月,随访时间为(96±12)个月(范围:84~108个月)。 结果: (1)临床特点:手术组患者的初始治疗时美国东部肿瘤协作组(ECOG)评分、肿瘤最大径≥4 cm的比例、FIGO 2018分期(包括Ⅲc1期和Ⅲc2期)、治疗时间、治疗费用分别与放疗组比较,差异均有统计学意义(P均<0.01)。(2)预后:①不同期别的Ⅲc期子宫颈鳞癌患者(488例):对于439例Ⅲc1期患者,手术组、放疗组患者的7年生存率分别为83.6%、52.9%,两组比较,差异有统计学意义(P<0.001);对于49例Ⅲc2期患者,手术组、放疗组患者的7年生存率分别为48.0%、33.3%,两组比较,差异无统计学意义(P=0.296)。②肿瘤最大径≥4 cm的患者(278例):对于246例Ⅲc1期患者,手术组、放疗组患者的7年生存率分别为81.2%、51.9%,两组比较,差异有统计学意义(P<0.001);分层分析显示,手术组(299例)Ⅲc1期患者中肿瘤最大径≥4 cm比例为46.2%(138/299),放疗组(140例)为77.1%(108/140),两组比较,差异有统计学意义(P<0.001);进一步分层分析,将放疗组中原FIGO 2009分期为Ⅱb期的肿瘤最大径≥4 cm的患者提取出来,共有46例,其7年生存率为67.4%,与手术组(为81.2%)比较,差异无统计学意义(P=0.052)。对于32例Ⅲc2期患者中,手术组、放疗组患者的7年生存率分别为50.0%、37.5%,两组比较,差异无统计学意义(P=0.157)。③髂总淋巴结有转移的患者(126例):手术组、放疗组患者的7年生存率分别为73.8%、57.4%,两组比较,差异无统计学意义(P=0.051)。(3)并发症发生率:手术组患者的淋巴囊肿、肠梗阻发生率[分别为30.2%(98/324)、7.7%(25/324)]均高于放疗组[分别为0(0/164)、1.2%(2/164)],输尿管梗阻、急性放射性肠炎、慢性放射性肠炎发生率[分别为8.3%(27/324)、54.3%(176/324)、7.4%(24/324)]均低于放疗组[分别为36.0%(59/164)、73.2%(120/164)、20.7%(34/164)],两组分别比较,差异均有统计学意义(P均<0.01)。 结论: 对于符合手术条件的Ⅲc1期子宫颈鳞癌患者,即使肿瘤最大径≥4 cm,无论是否存在盆腔淋巴结转移(不包括髂总淋巴结转移),根治性手术联合术后辅助放化疗和根治性放疗±同步化疗均为可接受的治疗方式。对于Ⅲc2期或髂总淋巴结有转移的子宫颈鳞癌患者,两种治疗方式患者的生存率无明显差异,基于治疗时长和经济学考虑,推荐患者选用根治性放疗±同步化疗方案。.
引用
- Feng T, Shou HF, Yuan SH, et al. [Treatment and prognosis analysis of 488 patients with FIGO 2018 stage Ⅲc squamous cervical cancer]. Zhonghua Fu Chan Ke Za Zhi. 2023. PMID: 37217343. doi:10.3760/cma.j.cn112141-20230128-00028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。